Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
2010-6-23
pubmed:abstractText
Recent evidence suggests a critical role for the intracellular signaling protein glycogen synthase kinase-3 (GSK3) in hyperactivity associated with dopaminergic transmission. Here, we investigated whether activation of GSK3 is necessary for the expression of behaviors specifically produced by dopamine D1 receptor activation. To assess the role of GSK3 in dopamine D1 receptor-induced hyperactivity, mice were pretreated with the selective GSK3 inhibitor SB 216763 (0.25-7.5mg/kg, i.p.) or its vehicle prior to administration of the dopamine D1 receptor full-agonist SKF-82958 (1.0mg/kg, i.p.) or saline control. Inhibition of GSK3 via SB 216763 dose-dependently reduced ambulatory and stereotypic activity produced by SKF-82958. These data implicate a role for GSK3 in the behavioral manifestations associated with dopamine D1 receptor activation.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-10037507, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-10450875, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-11033082, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-11527574, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-12388598, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-12504922, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-14631045, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-15044694, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-15315719, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-16000217, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-17101033, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-17251429, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-17552518, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-1762683, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-1825729, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-1839178, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-19328817, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-2568596, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-4403305, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-7903456, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-8083758, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-8463063, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-8628395, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-9097408, http://linkedlifedata.com/resource/pubmed/commentcorrection/20347018-9457173
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1873-2747
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2010 Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
31
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
184-7
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice.
pubmed:affiliation
Department of Pharmacology and the Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, United States. jsmiller@temple.edu
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural